JW (Cayman) Therapeutics Co. Ltd (2126.HK)

HKD 1.66

(3.11%)

Long Term Debt Summary of JW (Cayman) Therapeutics Co. Ltd

  • JW (Cayman) Therapeutics Co. Ltd's latest annual long term debt in 2023 was 197.79 Million CNY , up 113.83% from previous year.
  • JW (Cayman) Therapeutics Co. Ltd's latest quarterly long term debt in 2024 Q2 was 141.1 Million CNY , down 0.0% from previous quarter.
  • JW (Cayman) Therapeutics Co. Ltd reported annual long term debt of 92.5 Million CNY in 2022, down -2.63% from previous year.
  • JW (Cayman) Therapeutics Co. Ltd reported annual long term debt of 95 Million CNY in 2021, down -5.0% from previous year.
  • JW (Cayman) Therapeutics Co. Ltd reported quarterly long term debt of 133.77 Million CNY for 2023 Q2, down 0.0% from previous quarter.
  • JW (Cayman) Therapeutics Co. Ltd reported quarterly long term debt of 197.79 Million CNY for 2023 Q4, down 0.0% from previous quarter.

Annual Long Term Debt Chart of JW (Cayman) Therapeutics Co. Ltd (2023 - 2018)

Historical Annual Long Term Debt of JW (Cayman) Therapeutics Co. Ltd (2023 - 2018)

Year Long Term Debt Long Term Debt Growth
2023 197.79 Million CNY 113.83%
2022 92.5 Million CNY -2.63%
2021 95 Million CNY -5.0%
2020 100 Million CNY -93.2%
2019 1.47 Billion CNY 9368.9%
2018 15.53 Million CNY 0.0%

Peer Long Term Debt Comparison of JW (Cayman) Therapeutics Co. Ltd

Name Long Term Debt Long Term Debt Difference
Uni-Bio Science Group Limited 30.61 Million HKD -546.119%
CK Life Sciences Int'l., (Holdings) Inc. 4.27 Billion HKD 95.371%